1. Home
  2. TC vs PLYX Comparison

TC vs PLYX Comparison

Compare TC & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TuanChe Limited

TC

TuanChe Limited

HOLD

Current Price

$1.55

Market Cap

247.8M

ML Signal

HOLD

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$2.63

Market Cap

271.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TC
PLYX
Founded
2010
2014
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
247.8M
271.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
TC
PLYX
Price
$1.55
$2.63
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
9.7K
152.5K
Earning Date
03-28-2025
05-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$2.01
52 Week High
$19.99
$9.18

Technical Indicators

Market Signals
Indicator
TC
PLYX
Relative Strength Index (RSI) 13.07 48.29
Support Level $0.53 $2.58
Resistance Level $11.40 $3.41
Average True Range (ATR) 1.06 0.20
MACD -0.53 0.10
Stochastic Oscillator 0.98 78.92

Price Performance

Historical Comparison
TC
PLYX

About TC TuanChe Limited

Token Cat Ltd has two reportable business segments: automotive electronics resale business and advertising business. The automotive electronics resale business focuses on sourcing, holding, and reselling automotive electronics products, and includes sales of automotive electronic component equipment and accessories, mainly consisting of communication device and power module. The Company procures products from third-party suppliers and resells them to customers through its sales channels. The advertising business currently consists mainly of proxy advertising services, through which the Company helps clients promote their brands, services and products on third-party online platforms. The automotive electronics resale business segment generates maximum revenue.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: